Announcement • 13h
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report First Half, 2026 Results on Aug 28, 2026 Beijing Aosaikang Pharmaceutical Co., Ltd. announced that they will report first half, 2026 results on Aug 28, 2026 Declared Dividend • Jun 15
Dividend of CN¥0.12 announced Dividend of CN¥0.12 is the same as last year. Ex-date: 18th June 2026 Payment date: 18th June 2026 Dividend yield will be 0.9%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is well covered by both earnings (43% earnings payout ratio) and cash flows (31% cash payout ratio). The dividend has remained flat since 7 years ago. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 52% to shift the payout ratio to a potentially unsustainable range, which is more than the 20% EPS decline seen over the last 5 years. Valuation Update With 7 Day Price Move • May 28
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥14.80, the stock trades at a trailing P/E ratio of 51.6x. Average trailing P/E is 34x in the Pharmaceuticals industry in China. Total returns to shareholders of 41% over the past three years. Reported Earnings • Apr 30
First quarter 2026 earnings released: EPS: CN¥0.09 (vs CN¥0.06 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.09 (up from CN¥0.06 in 1Q 2025). Revenue: CN¥481.8m (down 5.3% from 1Q 2025). Net income: CN¥84.5m (up 54% from 1Q 2025). Profit margin: 18% (up from 11% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Announcement • Apr 29
Beijing Aosaikang Pharmaceutical Co., Ltd., Annual General Meeting, May 29, 2026 Beijing Aosaikang Pharmaceutical Co., Ltd., Annual General Meeting, May 29, 2026, at 14:00 China Standard Time. Location: 5F, Huifeng Hotel, Nanjing, Jiangsu China Announcement • Mar 31
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026 Beijing Aosaikang Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥15.60, the stock trades at a trailing P/E ratio of 56.4x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total returns to shareholders of 71% over the past three years. Buy Or Sell Opportunity • Mar 02
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 14% to CN¥14.82. The fair value is estimated to be CN¥18.76, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥19.02, the stock trades at a trailing P/E ratio of 68.8x. Average trailing P/E is 34x in the Pharmaceuticals industry in China. Total returns to shareholders of 138% over the past three years. New Risk • Jan 06
New major risk - Revenue and earnings growth Earnings have declined by 38% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Announcement • Dec 31
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026 Beijing Aosaikang Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026 Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥16.45, the stock trades at a forward P/E ratio of 64x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 85% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥24.63 per share. Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.07 (vs CN¥0.062 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.07 (up from CN¥0.062 in 3Q 2024). Revenue: CN¥426.5m (down 7.7% from 3Q 2024). Net income: CN¥63.3m (up 23% from 3Q 2024). Profit margin: 15% (up from 11% in 3Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Oct 13
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 10% to CN¥19.43. The fair value is estimated to be CN¥24.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.4% over the last 3 years. Earnings per share has grown by 72%. Revenue is forecast to grow by 41% in 2 years. Earnings are forecast to grow by 40% in the next 2 years. New Risk • Sep 16
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.1% average weekly change). Large one-off items impacting financial results. Announcement • Jul 02
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025 Beijing Aosaikang Pharmaceutical Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Buy Or Sell Opportunity • Jun 17
Now 24% undervalued after recent price drop Over the last 90 days, the stock has fallen 3.8% to CN¥16.80. The fair value is estimated to be CN¥22.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 14% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 34% in 2 years. Earnings are forecast to grow by 65% in the next 2 years. Announcement • May 31
Beijing Aosaikang Pharmaceutical Co., Ltd. Approves Dividend for the Year 2024 Beijing Aosaikang Pharmaceutical Co., Ltd. announced at the AGM held on May 29, 2025, approved Cash dividend/10 shares (tax included) of CNY1.20000000 for the year 2024. Buy Or Sell Opportunity • May 22
Now 23% undervalued Over the last 90 days, the stock has risen 29% to CN¥17.03. The fair value is estimated to be CN¥22.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 14% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 34% in 2 years. Earnings are forecast to grow by 65% in the next 2 years. New Risk • May 17
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.7% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.8% average weekly change). Large one-off items impacting financial results. Reported Earnings • May 02
First quarter 2025 earnings released: EPS: CN¥0.06 (vs CN¥0.03 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.06 (up from CN¥0.03 in 1Q 2024). Revenue: CN¥508.6m (up 13% from 1Q 2024). Net income: CN¥54.7m (up 74% from 1Q 2024). Profit margin: 11% (up from 7.0% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 29% per year. Announcement • Apr 28
Beijing Aosaikang Pharmaceutical Co., Ltd., Annual General Meeting, May 29, 2025 Beijing Aosaikang Pharmaceutical Co., Ltd., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time. Location: 5F, Huifeng Hotel, Nanjing, Jiangsu China New Risk • Apr 22
New major risk - Revenue and earnings growth Earnings have declined by 54% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 54% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Large one-off items impacting financial results. New Risk • Mar 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Large one-off items impacting financial results. Announcement • Mar 31
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Apr 28, 2025 Beijing Aosaikang Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Apr 28, 2025 Buy Or Sell Opportunity • Mar 07
Now 29% overvalued after recent price rise Over the last 90 days, the stock has risen 18% to CN¥16.63. The fair value is estimated to be CN¥12.94, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 29% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to decline by 8.8% in the next 2 years. Announcement • Jan 19
Innovent Biologics, Inc. and Jiangsu Aosaikang Pharmaceutical Co. Ltd. Jointly Announce NMPA Approval of Limertinib, a Third-Generation EGFR TKI for the Treatment of Lung Cancer Innovent Biologics, Inc. and Jiangsu Aosaikang Pharmaceutical Co. Ltd. jointly announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) of limertinib for the treatment of adult patients with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC). Limertinib is the 14th product in Innovent's commercial portfolio and represents a cutting-edge addition to its strong TKI franchise, offering an innovative precision therapy option to lung cancer patients. A Phase 2b pivotal study evaluating 301 patients with locally advanced or metastatic EGFR T790M-mutated NSCLC demonstrated limertinib's robust efficacy and safety profile. Independent review committee(IRC) assessment showed an overall response rate (ORR) of 68.8% and a disease control rate (DCR) of 92.4%. The median progression-free survival (PFS) reached 11.0 months, with a median duration of response (DoR) of 11.1 months. For patients with assessable central nervous system (CNS) lesions (N=99), the CNS best-ORR was 65.9% with a median PFS of 10.6 months. The safety profile aligned with other EGFR-targeting agents in its class. Additionally, limertinib met its primary endpoint in a Phase 3 clinical trial comparing it to gefitinib for first-line treatment of locally advanced or metastatic NSCLC harboring EGFR mutations. A separate NDA for the first-line treatment in adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 L858R mutations is currently under NMPA review. Lung cancer remains one of the deadliest and most common cancers globally[i], with NSCLC accounting for about 85% of cases. Around 70% of NSCLC patients are diagnosed at locally advanced or metastatic disease stages that cannot be surgically resected. EGFR mutations are particularly prevalent in Asian NSCLC patients, affecting 30% to 50% of cases. EGFR-TKIs are the recommended first-line standard of care for this group, with third-generation EGFR inhibitors offering the broadest applicability. Limertinib is an orally-administrated, third-generation EGFR TKI with proprietary rights, approved by the China's NMPA for the treatment of adult patients with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC). A second NDA is under NMPA review for first-line treatment of adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 L858R mutations. The drug demonstrated success in a multi-center, randomized, double-blind, controlled Phase 3 clinical trial comparing its efficacy and safety of to gefitinib in first-line treatment of patients with locally advanced or metastatic NSCLC harboring EGFR mutations. With the primary endpoint met, results will be presented at upcoming academic conferences or published in academic journals. In October 2024, Innovent and ASK Pharm entered into a strategic collaboration and license agreement for limertinib in Mainland China. Announcement • Dec 31
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Apr 28, 2025 Beijing Aosaikang Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on Apr 28, 2025 Reported Earnings • Nov 01
Third quarter 2024 earnings released: EPS: CN¥0.062 (vs CN¥0.029 loss in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.062 (up from CN¥0.029 loss in 3Q 2023). Revenue: CN¥461.9m (up 13% from 3Q 2023). Net income: CN¥51.4m (up CN¥77.6m from 3Q 2023). Profit margin: 11% (up from net loss in 3Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Announcement • Sep 30
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Beijing Aosaikang Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Reported Earnings • Aug 31
Second quarter 2024 earnings released: EPS: CN¥0.053 (vs CN¥0.10 loss in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.053 (up from CN¥0.10 loss in 2Q 2023). Revenue: CN¥474.1m (up 27% from 2Q 2023). Net income: CN¥44.0m (up CN¥133.9m from 2Q 2023). Profit margin: 9.3% (up from net loss in 2Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance. Announcement • Jun 29
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Beijing Aosaikang Pharmaceutical Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 Announcement • Apr 30
Beijing Aosaikang Pharmaceutical Co., Ltd., Annual General Meeting, May 29, 2024 Beijing Aosaikang Pharmaceutical Co., Ltd., Annual General Meeting, May 29, 2024, at 14:00 China Standard Time. Location: 5F, Jiangning Huifeng Hotel, Nanjing, Jiangsu China Reported Earnings • Apr 29
First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.07 loss in 1Q 2023) First quarter 2024 results: EPS: CN¥0.03 (up from CN¥0.07 loss in 1Q 2023). Revenue: CN¥448.5m (up 33% from 1Q 2023). Net income: CN¥31.5m (up CN¥100.1m from 1Q 2023). Profit margin: 7.0% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 101 percentage points per year, which is a significant difference in performance. Announcement • Mar 30
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024 Beijing Aosaikang Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Apr 29, 2024 Announcement • Dec 30
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 29, 2024 Beijing Aosaikang Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results on Apr 29, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: CN¥0.029 loss per share (vs CN¥0.19 loss in 3Q 2022) Third quarter 2023 results: CN¥0.029 loss per share (improved from CN¥0.19 loss in 3Q 2022). Revenue: CN¥407.9m (down 18% from 3Q 2022). Net loss: CN¥26.2m (loss narrowed 68% from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 31
Second quarter 2023 earnings released: CN¥0.10 loss per share (vs CN¥0.004 loss in 2Q 2022) Second quarter 2023 results: CN¥0.10 loss per share (further deteriorated from CN¥0.004 loss in 2Q 2022). Revenue: CN¥373.3m (down 21% from 2Q 2022). Net loss: CN¥89.9m (loss widened CN¥83.0m from 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance. Announcement • May 06
Beijing Aosaikang Pharmaceutical Co., Ltd., Annual General Meeting, May 26, 2023 Beijing Aosaikang Pharmaceutical Co., Ltd., Annual General Meeting, May 26, 2023, at 14:00 China Standard Time. Agenda: To consider 2022 work report of the board of directors; to consider 2022 annual report and its summary; to consider 2022 annual accounts; to consider 2022 profit distribution plan; to consider reappointment of 2023 audit firm; to consider 2023 remuneration plan for directors and senior management; to consider amendments to some of the Company's articles of association; and to consider 2022 work report of the supervisory committee. Reported Earnings • Apr 29
Full year 2022 earnings released: CN¥0.24 loss per share (vs CN¥0.41 profit in FY 2021) Full year 2022 results: CN¥0.24 loss per share (down from CN¥0.41 profit in FY 2021). Revenue: CN¥1.87b (down 40% from FY 2021). Net loss: CN¥225.8m (down 159% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Announcement • Dec 19
Beijing Aosaikang Pharmaceutical Co., Ltd.(XSEC:002755) dropped from S&P Global BMI Index Beijing Aosaikang Pharmaceutical Co., Ltd.(XSEC:002755) dropped from S&P Global BMI Index Board Change • Dec 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Xiaowen Wang was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 31
Third quarter 2022 earnings released: CN¥0.19 loss per share (vs CN¥0.14 profit in 3Q 2021) Third quarter 2022 results: CN¥0.19 loss per share (down from CN¥0.14 profit in 3Q 2021). Revenue: CN¥495.7m (down 36% from 3Q 2021). Net loss: CN¥80.7m (down 163% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥8.87, the stock trades at a trailing P/E ratio of 63.7x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total loss to shareholders of 42% over the past three years. Reported Earnings • Aug 29
Second quarter 2022 earnings released: CN¥0.004 loss per share (vs CN¥0.09 profit in 2Q 2021) Second quarter 2022 results: CN¥0.004 loss per share (down from CN¥0.09 profit in 2Q 2021). Revenue: CN¥475.0m (down 36% from 2Q 2021). Net loss: CN¥6.87m (down 108% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Announcement • Jun 11
Beijing Aosaikang Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2021, Payable on June 20, 2022 Beijing Aosaikang Pharmaceutical Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 1.00000000 on A shares for the year 2021. Record date is 17 June 2022. Ex-date is 20 June 2022. Payment date is 20 June 2022. Announcement • May 24
Beijing Aosaikang Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021 Beijing Aosaikang Pharmaceutical Co., Ltd. approved a cash dividend of CNY 1.00000000 per 10 shares (tax included) for the year 2021, at its AGM held on 20 May 2022. Announcement • May 08
Beijing Aosaikang Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021 Beijing Aosaikang Pharmaceutical Co., Ltd. proposed a final cash dividend of CNY 1.00000000 for every 10 shares (tax included) for the year 2021. Announcement • May 07
Beijing Aosaikang Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2022 Beijing Aosaikang Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2022, at 14:00 China Standard Time. Agenda: To consider 2021 work report of the board of directors; to consider 2021 annual report and its summary; to consider 2021 annual accounts; to consider 2021 profit distribution plan; to consider reappointment of 2022 audit firm; to consider 2022 remuneration plan for directors and senior management; to consider amendments to the Company's some articles of association; to consider amendments to the Company's rules of procedure governing shareholders' general meetings; to consider amendments to the Company's rules of procedure governing the board meetings; and to consider other matters. Reported Earnings • May 02
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint First quarter 2022 results: EPS: CN¥0.02 (down from CN¥0.19 in 1Q 2021). Revenue: CN¥535.5m (down 43% from 1Q 2021). Net income: CN¥19.4m (down 89% from 1Q 2021). Profit margin: 3.6% (down from 19% in 1Q 2021). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 11%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Board Change • Mar 29
High number of new directors Non-Independent Director Xiaowen Wang was the last director to join the board, commencing their role in 2022. Announcement • Feb 22
Beijing Aosaikang Pharmaceutical Co., Ltd. Announces Directorate Appointments Beijing Aosaikang Pharmaceutical Co., Ltd., at its Extraordinary General Meeting of 2022 held on 18 February 2022 elected Wang Xiaowen, Zhou Suling and Ma Jingfei as non-independent directors. Reported Earnings • Aug 30
Second quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.14 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥742.6m (down 6.4% from 2Q 2020). Net income: CN¥84.9m (down 30% from 2Q 2020). Profit margin: 11% (down from 15% in 2Q 2020). The decrease in margin was driven by lower revenue. Announcement • May 21
Beijing Aosaikang Pharmaceutical Co., Ltd. Approves 2020 Profit Distribution Plan Beijing Aosaikang Pharmaceutical Co., Ltd. approved 2020 profit distribution plan of Cash dividend/10 shares (tax included) CNY 2.00000000 at its Annual General Meeting of 2020 on 19 May 2021. Announcement • Apr 29
Beijing Aosaikang Pharmaceutical Co., Ltd. Announces Cash Dividend for the Year 2020 Beijing Aosaikang Pharmaceutical Co., Ltd. announced Cash dividend/10 shares (tax included) of CNY 2.00000000 for the year 2020. Reported Earnings • Apr 29
First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.11 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥931.5m (up 31% from 1Q 2020). Net income: CN¥178.3m (up 67% from 1Q 2020). Profit margin: 19% (up from 15% in 1Q 2020). The increase in margin was driven by higher revenue. Announcement • Apr 28
Beijing Aosaikang Pharmaceutical Co., Ltd. (SZSE:002755) agreed to acquire 60% stake in Jiangsu Vedkang Medical Science and Technology Co., Ltd. from Changzhou Beiruishi Enterprise Management Co., Ltd., Changzhou Yisiyuan Enterprise Management Co., Ltd., Zhuang Xiaojin and Miao Donglin for approximately CNY 830 million. Beijing Aosaikang Pharmaceutical Co., Ltd. (SZSE:002755) agreed to acquire 60% stake in Jiangsu Vedkang Medical Science and Technology Co., Ltd. from Changzhou Beiruishi Enterprise Management Co., Ltd., Changzhou Yisiyuan Enterprise Management Co., Ltd., Zhuang Xiaojin and Miao Donglin for approximately CNY 830 million on April 22, 2021. Under the terms of consideration, 30% equity of the target company will pay by cash CNY 417 million and the rest 30% will pay by issuing 28.6 million shares, at CNY 14.59 per share, total valued CNY 417 million. Changzhou Beiruishi Enterprise Management's shareholder approved the deal and as of April 23, 2021, Beijing Aosaikang Pharmaceutical Co., Ltd's board approved the deal. The deal is subject to approval from China Securities Regulatory Commission. Jiangsu Vedkang Medical Science and Technology reported Total revenues of CNY 374.4 million, total assets of CNY 314.9 million, net income of CNY 98 million and Total common equity of CNY 111 million for the year ending December 31, 2020. Is New 90 Day High Low • Jan 07
New 90-day low: CN¥12.69 The company is down 24% from its price of CN¥16.66 on 09 October 2020. The Chinese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. Is New 90 Day High Low • Dec 18
New 90-day low: CN¥14.38 The company is down 18% from its price of CN¥17.50 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Is New 90 Day High Low • Nov 24
New 90-day low: CN¥15.75 The company is down 12% from its price of CN¥17.80 on 26 August 2020. The Chinese market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 10.0% over the same period. Reported Earnings • Oct 26
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥674.1m, down 13% from the prior year. Total revenue was CN¥3.70b over the last 12 months, down 18% from the prior year. Is New 90 Day High Low • Oct 23
New 90-day low: CN¥15.78 The company is down 19% from its price of CN¥19.51 on 24 July 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. Announcement • Oct 19
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 26, 2020 Beijing Aosaikang Pharmaceutical Co., Ltd. announced that they will report Q3, 2020 results on Oct 26, 2020 Is New 90 Day High Low • Sep 28
New 90-day low: CN¥15.95 The company is down 16% from its price of CN¥18.90 on 30 June 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Announcement • Aug 10
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020 Beijing Aosaikang Pharmaceutical Co., Ltd. announced that they will report first half, 2020 results on Aug 26, 2020 